Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Assets: 2017-2024

Historic Assets for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $1.4 billion.

  • Crinetics Pharmaceuticals' Assets rose 27.59% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 27.59%. This contributed to the annual value of $1.4 billion for FY2024, which is 125.79% up from last year.
  • As of FY2024, Crinetics Pharmaceuticals' Assets stood at $1.4 billion, which was up 125.79% from $635.4 million recorded in FY2023.
  • Crinetics Pharmaceuticals' Assets' 5-year high stood at $1.4 billion during FY2024, with a 5-year trough of $183.4 million in FY2020.
  • Its 3-year average for Assets is $807.4 million, with a median of $635.4 million in 2023.
  • Data for Crinetics Pharmaceuticals' Assets shows a peak YoY skyrocketed of 125.79% (in 2024) over the last 5 years.
  • Over the past 5 years, Crinetics Pharmaceuticals' Assets (Yearly) stood at $183.4 million in 2020, then surged by 91.35% to $351.0 million in 2021, then climbed by 0.33% to $352.2 million in 2022, then soared by 80.41% to $635.4 million in 2023, then skyrocketed by 125.79% to $1.4 billion in 2024.